China Traditional Chinese Medicine Holdings Co. Limited (0570.HK) Bundle
From its founding in 1955 to its 1993 Hong Kong Main Board listing as 00570.HK, China Traditional Chinese Medicine Holdings Co. Limited has grown into an 18,000‑employee state‑owned leader in the TCM value chain-spanning cultivation, ISO‑certified quality control, concentrated granules and finished drugs-anchored by parent Sinopharm and a market capitalization of about $1.39 billion as of December 2025; the company's recent corporate milestones include a consortium bid valuing it at nearly $3 billion in early 2024 (later canceled in October 2024), the March 2025 appointment of Ms. Huang He as vice president, and an August 29, 2025 board meeting to review interim results, while its business model monetizes branded product sales (Yi Fang, Tian Jiang, Tong Ji Tang, Medi‑World), clinical services, herb supply and licensing, supported by R&D investments of roughly 10% of annual revenue, two CNAS‑accredited labs, 126 patents, a traceable quality assurance system, digital transformation efforts and a 'Dual Carbon Action' sustainability program that together shape its operational and financial trajectory
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK): Intro
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK) is a leading state-affiliated enterprise in the traditional Chinese medicine (TCM) industry, with roots back to 1955. The group operates across the full TCM value chain - from cultivation and sourcing of Chinese medicinal materials to R&D, production of decoction pieces, concentrated formula granules, finished drugs, TCM health products, and operation of TCM institutions and service networks. The company is internationally listed on the Main Board of the Hong Kong Stock Exchange (stock code 0570.HK) since 1993, and remains a major platform for state-led consolidation and industrial leadership in TCM.- Founded: 1955
- HKEX Listing: 1993 (Main Board, 00570.HK)
- Parent/major stakeholder: Sinopharm Group and other state-related entities
- Privatization bid (consortium led by Sinopharm): early 2024 - valued at nearly US$3.0 billion (offer ultimately cancelled Oct 2024)
- Senior management update: Ms. Huang He appointed Vice President, March 2025
- Board activity: Board meeting announced for August 29, 2025 to consider interim results for six months ended June 30, 2025
- Industry standing (as of Dec 2025): leading in R&D, production and market scale of TCM formula granules; prominent quality control and traceability systems
| Year / Date | Event | Significance |
|---|---|---|
| 1955 | Establishment of the enterprise | Origin of the group's TCM operations and cultivation bases |
| 1993 | Listed on HKEX Main Board (00570.HK) | Expanded capital base and international investor access |
| Early 2024 | Consortium privatization bid led by Sinopharm (≈US$3.0bn) | Proposed consolidation under state-owned enterprises; bid later cancelled Oct 2024 |
| Oct 2024 | Privatization proposal cancelled | Company remained publicly listed and continued investor reporting |
| Mar 2025 | Ms. Huang He appointed Vice President | Strengthened strategic planning and HR leadership |
| Aug 29, 2025 (announced) | Board meeting to consider interim results (6 months ended Jun 30, 2025) | Regular shareholder engagement and financial disclosure |
| Dec 2025 | Market/operational status | Leader in formula granules, R&D and traceable quality assurance |
- Sale of TCM decoction pieces and concentrated formula granules - distributed to hospitals, clinics, pharmacies and end-consumers.
- Manufacture and sales of finished TCM drugs - prescription and OTC products for domestic and selected export markets.
- TCM health and nutraceutical products - branded consumer goods sold through pharmacies, hospitals and e-commerce channels.
- Provision of TCM clinical services and operation of TCM institutions - revenue from outpatient services, hospital partnerships, and institutional supply.
- Supply chain and raw materials business - cultivation, processing and trading of Chinese medicinal materials (vertical integration reduces cost and supports quality traceability).
- R&D, technology licensing and quality-control services - monetizing proprietary formula granules, testing and traceability platforms with partners.
- Integrated value chain from cultivation to finished product enabling margin capture at multiple stages.
- Leading position in formula granules R&D and production capacity, supported by traceability systems for raw materials and quality control.
- Strategic backing and capital access via Sinopharm and state-affiliated investors, enabling scale investments and market consolidation initiatives.
- Multi-channel distribution including hospital procurement, retail pharmacies, institutional clients and e-commerce.
- Regulatory scrutiny and policy shifts affecting TCM standards, reimbursement and state consolidation plans.
- Dependence on raw material supply and agricultural yields for key Chinese medicinal herbs (price and availability volatility).
- Competition from private and international pharmaceutical firms, and from alternative medical therapies.
- Market sentiment impacts from attempted privatization and state-driven restructuring moves.
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK): History
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK) is a major integrated Traditional Chinese Medicine (TCM) group headquartered in Foshan, Guangdong. Established through consolidation of several regional TCM manufacturers and distributors, the company developed capabilities across R&D, manufacturing, distribution and retail of TCM finished products, proprietary medicines and health supplements.- Parent and ownership: subsidiary of China National Pharmaceutical Group Corporation (Sinopharm Group), a state-owned enterprise that holds a significant stake.
- Listing: Main Board of the Hong Kong Stock Exchange, stock code 00570.HK, providing access to international capital markets.
- Privatization attempt: In early 2024 a Sinopharm‑led consortium proposed a takeover valuing the company at nearly $3.0 billion; the bid was withdrawn/cancelled in October 2024.
- Market value: As of December 2025 market capitalization ~ $1.39 billion.
- Workforce and HQ: ~18,000 employees; headquarters and management center in Foshan, Guangdong province.
- Corporate governance: board comprises executive directors, non-executive directors and independent non-executive directors to ensure balanced oversight.
| Key item | Detail / Value |
|---|---|
| Company name (HKEx) | China Traditional Chinese Medicine Holdings Co. Limited (00570.HK) |
| Parent | China National Pharmaceutical Group Corporation (Sinopharm Group) |
| Market capitalization (Dec 2025) | ≈ $1.39 billion |
| Privatization bid (early 2024) | Consortium led by Sinopharm; implied valuation ≈ $3.0 billion (bid cancelled Oct 2024) |
| Employees | ≈ 18,000 |
| Headquarters | Foshan, Guangdong, China |
| Listing | Hong Kong Main Board |
- Manufacturing: production of patent and proprietary TCM products (granules, pills, capsules, decoctions) for domestic and export markets; revenue drivers include scale manufacturing and GMP-certified facilities.
- Distribution & wholesale: national distribution network supplying hospitals, clinics, retail pharmacies and community health centers-bulk sales contribute a large share of turnover.
- Retail and e‑commerce: branded retail outlets and online channels selling finished consumer health products and proprietary formulas; margin improvement from direct-to-consumer sales.
- R&D & licensing: development of new TCM formulations, clinical trials, and licensing/co‑development agreements that generate milestone and royalty income.
- Contract manufacturing & OEM: third‑party manufacturing contracts for other pharmaceutical/TCM brands provide capacity utilization and incremental revenue.
| Metric | Typical range / example |
|---|---|
| Market capitalization (Dec 2025) | ≈ $1.39 billion |
| Privatization implied valuation (early 2024) | ≈ $3.0 billion |
| Employees | ≈ 18,000 |
| Primary markets | Mainland China (hospitals, pharmacies, retail), exports regionally |
| Revenue drivers | Manufacturing output, distribution volume, retail/e‑commerce growth, R&D licensing |
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK): Ownership Structure
- Mission and Values
- Key value pillars
- Strategic alignment: Focus on national TCM development policies to build a complete, synergistic industrial chain.
- High-quality development: Prioritize product quality, standardized production, and scale to lead market segments.
- Technological innovation: Invest in R&D and scale up large‑scale application of technological achievements to improve product competitiveness.
- Quality assurance: Maintain traceable QMS across cultivation, processing, and distribution to ensure safety and efficacy.
- Environmental stewardship: Implement "Dual Carbon Action" measures to reduce CO2 emissions and improve energy efficiency.
- Social responsibility: Support rural revitalization, agricultural partners, and community programs tied to TCM raw-material sourcing.
- How it works & makes money
- Raw-material cultivation and procurement - proprietary or contracted herb farms supplying quality-controlled inputs.
- Manufacturing - processing TCM extracts, finished proprietary Chinese medicine products, and decoction pieces at scale.
- Product sales - OTC TCM products, prescription-class drugs, health supplements and functional foods sold via hospitals, pharmacies, distributors and e‑commerce.
- R&D and licensing - development of standardized formulations and technologies, licensing or toll-manufacturing deals.
- Healthcare services and clinics - integrative TCM services and franchised/affiliate clinic networks where applicable.
- Ancillary incomes - by-products, packaging, logistics, and government subsidies tied to rural development or environmental programs.
| Revenue stream | Typical contribution (company-reported categories / illustrative) |
|---|---|
| Finished TCM products (OTC & prescription) | Largest single segment - often >40% of product revenue |
| Herbal raw materials & decoction pieces | Supply-chain sales and internal use - material margin stabilizer |
| R&D / licensing / toll-manufacturing | Growing share as technological outputs are commercialized |
| Healthcare services / clinics | Smaller but strategic for brand & patient flow |
| Other (logistics, packaging, subsidies) | Supportive, variable by region and policy incentives |
- Ownership and governance themes
- Ownership is typically a mix of controlling strategic shareholders (state‑linked or large private TCM groups), institutional investors, and retail free float on the HKEX.
- Governance emphasizes alignment with national TCM policy, board oversight of quality and sustainability, and disclosure of environmental/social initiatives (e.g., CO2 reduction targets under Dual Carbon Action plans).
- Financial discipline focuses on scaling high-margin formulations, improving manufacturing yield, and securing long-term supply stability through farm partnerships and traceability systems.
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK): Mission and Values
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK) positions itself as an integrated TCM enterprise committed to preserving traditional medicines while modernizing production, quality control and distribution. The company's stated mission emphasizes authentic raw-material sourcing, scientific validation of TCM efficacy and broad public accessibility through multiple channels.- Core purpose: safeguard authenticity and efficacy of TCM through vertical integration and scientific validation.
- Value pillars: quality assurance, traceability, innovation, sustainability and regulatory compliance.
- Strategic intent: build a leading industrial cluster for concentrated TCM products supported by digital transformation and R&D.
- Cultivation bases: a managed network of proprietary and contract cultivation bases across key TCM-producing regions to secure authentic geo-specific herbs and reduce supply-chain risk.
- Quality control: centralized QA/QC systems with batch-level traceability, adherence to ISO 9001 and local Good Manufacturing Practice (GMP) standards for herbal production and finished products.
- Manufacturing: in-house facilities produce concentrated TCM granules, extracts and finished formulations to maintain consistency and shelf stability.
- R&D and validation: ongoing clinical and laboratory research to validate efficacy and safety, with ~10% of annual revenue allocated to R&D activities.
- Distribution: omnichannel model - pharmacies, hospitals, retail outlets, institutional procurement and an expanding e-commerce presence for direct-to-consumer reach.
- Digital and policy adaptation: investments in digital platforms, supply-chain traceability systems and production automation to respond to regulatory changes and consumer trends.
| Metric | Figure / Note |
|---|---|
| Reported annual revenue (FY2023, approximate) | HK$2.1 billion |
| R&D spend | ~10% of annual revenue (c. HK$210 million) |
| Gross margin (approx.) | 25-35% (varies by product line) |
| Primary revenue drivers | Concentrated TCM granules, finished TCM products, raw herbal sales, contract manufacturing |
| Quality certifications | ISO 9001, local GMP certifications for manufacturing sites |
| Distribution reach | Pharmacies, hospitals, retail chains, e-commerce platforms |
- Product sales: majority of revenue from sales of concentrated TCM granules and finished herbal formulations sold to pharmacies, hospitals and consumers.
- Raw material sales and sourcing services: revenue from supplying authenticated herbs to other manufacturers and institutional buyers.
- Contract manufacturing and OEM: production services for third-party TCM brands and healthcare companies.
- Value-added services: digital platforms, traceability services, and licensing of standardized formulations.
- Traceable supply chain: direct control of cultivation bases reduces adulteration risk and supports premium pricing for authenticated herbs.
- Quality system and certifications: ISO 9001 and GMP adherence enable procurement by hospitals and institutional buyers that demand stringent standards.
- R&D intensity: allocating roughly 10% of revenue into R&D supports product differentiation, safety evaluation and potential clinical substantiation.
- Omnichannel distribution: combined offline and e-commerce presence broadens market access and supports margin optimization.
- Industrial cluster development: focus on building upstream-downstream integration to capture more value across the TCM lifecycle.
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK): How It Works
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK) is an integrated traditional Chinese medicine (TCM) group that commercializes TCM raw materials, decoction pieces, concentrated granules, finished drugs, retail products and related healthcare services. Its business model combines manufacturing, branded product sales, hospital/clinic services, retail pharmacy distribution and industry investments to monetize both products and TCM healthcare delivery.- Primary revenue streams: manufacturing & sale of TCM concentrated granules, decoction pieces and finished drugs; branded TCM health products; retail pharmacy and hospital channel sales; TCM clinical services (consultation, diagnosis, physiotherapy, prescriptions); sale of raw medicinal herbs; marketing, advertising and consulting; and property leasing.
- Operating segments/brands: Yi Fang (YiFang), Tian Jiang, Tong Ji Tang, Medi-World (and ancillary brands De Zhong, Feng Liao Xing).
- Distribution channels: public and private hospitals, chain and independent retail pharmacies, proprietary clinics/offline medical institutions, B2B distributors and e-commerce/omnichannel partners.
- Product manufacturing and sale: Industrial-scale production of concentrated TCM granules, decoction pieces and finished TCM pharmaceuticals. Margins derive from scale, control of raw herb sourcing and in-house processing facilities.
- Branded finished goods and OTC health products: Higher-margin branded items sold through retail pharmacies and distributors; pricing power tied to brand recognition (Yi Fang, Tong Ji Tang, Tian Jiang, Medi-World).
- Clinical services and prescriptions: Offline medical institutions deliver fee-for-service revenue (consultation, TCM physiotherapy, diagnosis) and drive prescription demand for in-house or recommended products.
- Wholesale and trading: Trading of pharmaceutical products and supply of decoction pieces to hospitals and clinics provides volume-based revenue and working-capital cycle benefits.
- Herb procurement and sales: Direct purchase, processing and resale of medicinal herbs; vertical integration reduces COGS and stabilizes supply chain.
- Value-added services: Marketing, advertising, consulting services to TCM stakeholders and co-branding partnerships generate service fees.
- Property leasing and asset income: Leasing of owned properties (clinics, warehouses) and investment returns from TCM-related industry investments.
| Metric | Illustrative / FY2023 (approx.) |
|---|---|
| Total revenue | HK$3.6-4.0 billion (group consolidated) |
| Revenue split by activity | Manufacturing & product sales ~55-65%; Clinical services & prescriptions ~15-25%; Wholesale/trading ~10-15%; Services & leasing ~5-10% |
| Gross margin (group) | ~25-32% |
| Net profit / (loss) | HK$50-250 million (depends on non-recurring items and impairment adjustments) |
| CapEx (annual) | HK$50-200 million (production and clinic expansion) |
| Inventory turnover | ~3-6 times/year (varies with herb seasonality) |
| Geographic mix | Mainland China ~85-95%; Hong Kong and others remainder |
- Scale of granule and decoction production: higher utilization reduces unit cost of concentrated granules-key to margin expansion.
- Brand premium: Established brand names (Yi Fang, Tong Ji Tang, Tian Jiang) command higher retail pricing and better shelf placement.
- Channel mix: Hospital tenders and large pharmacy chains provide volumes but tighter pricing; self-operated clinics and direct-to-consumer channels increase gross margin.
- Raw herb sourcing: Vertical integration into herb procurement stabilizes input costs, reduces quality risk and preserves margin during herb price volatility.
- Regulatory and product approvals: Product registrations and clinical endorsements materially affect market access and pricing power.
- Direct product sales: Manufacture concentrated granules → sell to hospitals/retailers/distributors → revenue recognized at shipment.
- Clinic-driven prescriptions: Patient consultation at proprietary clinic → practitioner prescribes Tian Jiang/Tong Ji Tang product → higher-margin in-clinic sale or redirected to partner pharmacy.
- Service & consulting: Provide marketing/advertising for third-party brand → fee income and potential revenue share on sales uplift.
| Function | Role in revenue generation |
|---|---|
| Manufacturing & QC | Produces granules, decoction pieces and finished drugs; ensures standards for hospital tenders and retail listings. |
| R&D & regulatory | Drives product development, registration and evidence to support clinical use and market acceptance. |
| Sales & distribution | Manages hospital tenders, pharmacy chains, distributors and e-commerce partners to maximize reach. |
| Clinical network | Operates offline institutions delivering services and prescribing products-key demand driver for branded items. |
| Sourcing & herb procurement | Secures raw materials, stabilizes costs and supports product quality claims. |
- Hospitals and TCM clinics: supply of decoction pieces, concentrated granules and finished drugs through tender and direct sale contracts.
- Retail pharmacies and chains: distribution of branded OTC and prescription TCM finished drugs.
- Proprietary clinics (offline medical institutions): clinical service fees plus product dispensing/prescription conversion.
- Wholesale distributors: broad geographic reach for bulk sales and small-channel penetration.
| Brand | Primary focus | Typical channel |
|---|---|---|
| Yi Fang | Herbal decoction granules & consumer health products | Retail pharmacies, e-commerce, clinics |
| Tian Jiang | Prepared slices/decoction pieces & hospital supplies | Hospitals, institutional buyers |
| Tong Ji Tang | Heritage TCM formulations & finished drugs | Hospitals, retail pharmacies |
| Medi-World | Healthcare services, specialised formulations | Clinics, health service partners |
- Herb price volatility and seasonal supply constraints can compress margins.
- Regulatory approvals, GMP compliance and product registrations affect time-to-market and sales recognition.
- Channel concentration (dependence on a few large hospital customers or pharmacy chains) can influence negotiating power and pricing.
- Brand reputation and clinical evidence impact premium pricing and prescription conversion.
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK): How It Makes Money
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK) generates revenue and value through vertical integration of the traditional Chinese medicine (TCM) supply chain - from R&D and raw herb sourcing to production of TCM formula granules, finished proprietary medicines, and distribution through hospital, retail and digital channels. Its market position, innovation profile and sustainability initiatives support pricing power, margin resilience and long-term customer trust.- Core revenue streams: production and sales of TCM formula granules, finished proprietary medicines, contract manufacturing and OEM services, licensing/patents, and distribution/retail margins.
- Competitive advantages: leading R&D, CNAS-accredited laboratories (2 added in 2024), traceable quality assurance systems and 126 patents granted in 2024.
- Operational focus: optimize business structure, tighten cost control, pursue digital transformation and strengthen supply-chain resilience to adapt to policy and market changes.
- ESG & sustainability: active 'Dual Carbon Action' plan and measurable CO2 emissions reductions positioning the company as an environmental leader in the TCM sector.
| Metric | Figure / Note |
|---|---|
| Market capitalization (Dec 2025) | Approximately $1.39 billion |
| 2024 patents granted | 126 |
| CNAS-accredited labs added (2024) | 2 laboratories |
| Leading product segments | TCM formula granules, finished proprietary medicines, contract manufacturing |
| Strategic priorities | Value creation, cost efficiency, technological innovation, digital transformation |
| ESG initiative | 'Dual Carbon Action' work plan with significant CO2 reductions |
- Revenue mechanics by activity:
- Formula granules: volume-driven sales to hospitals, clinics and pharmacies with premium for traceability/quality.
- Proprietary medicines: higher-margin branded products leveraging R&D and patent portfolio.
- Contract manufacturing/OEM: capacity monetization and steady cashflow from third-party clients.
- Licensing & technology services: monetization of patents and laboratory capabilities.
- Future outlook: maintaining leadership in quality control and industrial clustering, scaling digital channels and improving cost structure to protect margins amid regulatory and market shifts.
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.